Aurobindo Pharma plunges 8% as USFDA classifies oral solids plant as OAI

USFDA, that had conducted a Current Good Manufacturing Practice (cGMP) inspection at the company's Unit 7 an oral solids formulation manufacturing facility from Sept 19-27, 2019, issued 7 observations

Shares of Aurobindo Pharma slipped 8 per cent to Rs 467 on the BSE on Thursday after that the US drug regulator classified the inspection of the company’s oral solids formulation manufacturing facility of Unit VII as Official Action Indicated (OAI).

The drug company in exchange filing said it has received a letter from the US Food and Drug Administration (USFDA) classifying the inspection conducted at the aforesaid facility as OAI.

The USFDA, that had conducted a Current Good Manufacturing Practice (cGMP) inspection at the company’s Unit 7 an oral solids formulation manufacturing facility from September 19-27, 2019, issued 7